FDA signals upcoming rules for generative AI use in drug development

The FDA announced it intends to create regulatory guidance for the use of generative artificial intelligence in pharmaceutical research and development.

The move follows growing interest in AI tools that can design molecules, predict trial outcomes, and streamline data analysis, prompting regulators to consider safety, transparency, and bias issues.

In related health policy news, the administration issued a request for information on vaccine strategies after a recent executive order questioning the childhood immunization schedule, opening a 30‑day comment period.

The request asks whether new vaccine categories should be added to the existing framework that includes universal, risk‑based, and shared‑decision recommendations.

A separate consumer trend note highlighted a 12 % drop in soda purchases, underscoring broader shifts in health‑related behavior.